New FDA nod, Lupin’s Ranluspec steps into the US retina biosimilar race

With FDA approval as an interchangeable ranibizumab biosimilar, Lupin’s Ranluspec targets five major retinal indications and enters a crowded but fast-growing US eye-care market.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 9:41 AM ET. Details in the imprint.

Lupin’s newly approved Ranluspec, an interchangeable biosimilar to blockbuster eye drug Lucentis (ranibizumab), is the company’s latest bid to expand in the US ophthalmology market after securing Food and Drug Administration clearance for five key retinal indications and dual-dose formats. The FDA has designated ranibizumab-hkdz (Ranluspec) as interchangeable with Genentech’s Lucentis, meaning pharmacists can substitute it in place of the reference product subject to state laws, a status that could accelerate adoption in retina clinics facing cost pressures from biologic therapies. According to Lupin and US clinical data summaries, the approval covers neovascular (wet) age-related macular degeneration, macular edema after retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization, putting Ranluspec in direct competition with other ranibizumab biosimilars and anti-VEGF agents in one of ophthalmology’s most competitive segments. Eyecare industry reports on the FDA approval and its five indications.

What Ranluspec does and how it is positioned in the US eye-care market

Ranluspec is a ranibizumab biosimilar injection developed to inhibit vascular endothelial growth factor (VEGF), the same molecular target as Lucentis, with the goal of reducing abnormal blood vessel growth and leakage in the retina that can lead to vision loss in conditions such as wet AMD and diabetic macular edema. Lupin’s filing drew on comparative analytical, nonclinical, and clinical data designed to demonstrate that ranibizumab-hkdz matches the reference product in efficacy, safety, and immunogenicity, and the interchangeable designation recognizes that these data support automatic substitution at the pharmacy level under applicable laws. In an interview following approval, Cyrus Karkaria, president of Lupin’s Biotech Business, highlighted that Ranluspec will be available in prefilled syringes and vials at both 0.3 mg and 0.5 mg strengths, making it, according to Lupin, the first ranibizumab biosimilar to combine interchangeability with dual-format availability across both approved strengths, a packaging twist that is aimed at aligning with existing retina practice workflows and potentially reducing preparation time before injections. Modern Retina details the interchangeable designation and dual-format presentation.

Commercially, Ranluspec enters a US market where anti-VEGF injections for retinal disease are both clinically entrenched and economically under scrutiny, with payers and clinics looking for ways to manage biologic drug spend while maintaining access to sight-preserving therapy. Lupin is positioning Ranluspec as a way to broaden access to ranibizumab therapy by offering a lower-cost alternative to Lucentis without requiring physicians to change treatment protocols, which could appeal particularly to high-volume retina centers treating large numbers of Medicare and Medicaid patients. While specific US pricing has not yet been publicly confirmed, biosimilar discounts in ophthalmology and other biologic categories have typically ranged from mid-teens to more than 30 percent versus the reference product list price, and any meaningful rebate strategy from Lupin could pressure competitors as payers update formularies and buy-and-bill economics for retina practices. For Lupin, which has emphasized innovation and specialty portfolios in its recent communications, Ranluspec provides an anchor asset in US ophthalmology that can complement its broader biologics and complex generics pipeline as it seeks higher-margin growth beyond traditional oral generics. Lupin’s official announcement outlines the product’s positioning and indications.

Within Lupin’s portfolio, Ranluspec sits at the intersection of the company’s long-standing generics business and its newer biologics ambitions, as management continues to signal a strategy of moving up the value chain into complex therapies where regulatory and manufacturing barriers are higher. The retina segment is an attractive proving ground because of its high per-dose prices and chronic dosing schedules, which magnify the financial impact of biosimilar adoption for both payers and providers. For US patients and clinicians, the product adds another interchangeable option in a category that already includes other ranibizumab biosimilars, potentially increasing competition on price and contracting while keeping clinical outcomes aligned with the reference medicine. From an investor perspective, the product’s performance will be one of several contributors to Lupin’s specialty revenue mix alongside cardiovascular, respiratory, and other therapeutic areas, and it arrives at a time when the company’s equity is closely watched on Indian exchanges. Shares of Lupin (ISIN INE326A01037) closed on the BSE in Mumbai at INR 2,268.70 on 06/15/2026, according to Business Standard data, underscoring the market’s focus on execution in biosimilars and complex generics.

Ranluspec quick profile: the key facts

• Product: Ranluspec (ranibizumab-hkdz)
• Manufacturer: Lupin Limited
• Category: New Release/Launch - ophthalmology biosimilar
• Launch date: FDA approval announced June 2026 (US)
• MSRP / Price: Not yet publicly disclosed; expected to be discounted vs. Lucentis in the US
• Availability: US market, injectable formulation for intravitreal use in retina clinics and hospitals
• Target audience: Adult patients with wet AMD, macular edema following RVO, diabetic macular edema, diabetic retinopathy, or myopic CNV, as treated by ophthalmologists and retina specialists
• Key differentiator / USP: Interchangeable ranibizumab biosimilar with dual-format availability (vials and prefilled syringes) across both 0.3 mg and 0.5 mg strengths

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.